NCT07703735

Brief Summary

This retrospective cohort study aimed to evaluate long-term oncologic outcomes after ABO-incompatible living donor liver transplantation (LDLT) for hepatocellular carcinoma (HCC). Patients who underwent LDLT between January 2012 and December 2023 at a single tertiary center were included. Outcomes of interest included overall survival and recurrence patterns, with a focus on differences in time to recurrence between ABO-compatible and ABO-incompatible recipients.

Trial Health

83
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
371

participants targeted

Target at P75+ for all trials

Timeline
5mo left

Started Jan 2012

Longer than P75 for all trials

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress97%
Jan 2012Dec 2026

Study Start

First participant enrolled

January 1, 2012

Completed
14 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

July 7, 2026

Completed
7 days until next milestone

First Posted

Study publicly available on registry

July 14, 2026

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Expected
Last Updated

July 14, 2026

Status Verified

July 1, 2026

Enrollment Period

14 years

First QC Date

July 7, 2026

Last Update Submit

July 12, 2026

Conditions

Liver TransplantationHepatocellular Carcinoma (HCC)

Outcome Measures

Primary Outcomes (1)

  • Overall Survival, Recurrence-free Survival

    Time from liver transplantation until death from any cause

    Up to 10 years after transplantation

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

This study included consecutive adult patients who underwent living donor liver transplantation for hepatocellular carcinoma at the National Cancer Center, Korea. Patients were stratified according to ABO compatibility.

You may qualify if:

  • Underwent living donor liver transplantation for HCC
  • Transplantation between Jan 2012 - Dec 2023

You may not qualify if:

  • Deceased donor liver transplantation
  • Re-transplantation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsLiver NeoplasmsDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesLiver Diseases

Study Officials

  • Seoung Hoon Kim, MD, PhD

    National Cancer Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR INVESTIGATOR
PI Title
National Cancer Center, Korea

Study Record Dates

First Submitted

July 7, 2026

First Posted

July 14, 2026

Study Start

January 1, 2012

Primary Completion

December 31, 2025

Study Completion (Estimated)

December 31, 2026

Last Updated

July 14, 2026

Record last verified: 2026-07